Beta-Sitosterol-Conjugated Sinapic Acid-Engineered Nanoliposome: Biomucoadhesive and Enzyme-Responsive Targeted Oral Therapy in Ulcerative Colitis DOI

Kanika,

Ajay Kumar, Anas Ahmad

и другие.

ACS Applied Materials & Interfaces, Год журнала: 2025, Номер unknown

Опубликована: Апрель 29, 2025

Developing oral drug delivery systems is promising for ulcerative colitis (UC). However, the key challenges, including formulation degradation under harsh gastric conditions, poor targeting efficiency, and limited colonic residence, lead to therapeutic efficacy that still needs be tackled. Effective treatment requires a safe, efficacious, enzyme- pH-responsive, biomucoadhesive system overcome these challenges. Therefore, we have developed chitosan-armored 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) nanoliposomes amalgamated with synthesized beta-sitosterol-sinapic acid (Be-S) conjugate, further encapsulated 3,4-methylenedioxy-β-nitrostyrene (MNS) as NLRP3 inhibitor, termed C@MN@DMBe-S, limitation of free MNS sinapic acid. Formulated by thin-film hydration method processed through extrusion, unilamellar liposomes demonstrated structural stability mucoadhesive properties due chitosan coating. This configuration protected from acidic environment allowed retention in inflamed colon 48 h. The enzyme-responsive C@MN@DMBe-S nanoliposome releases at site via esterase activity, providing sustained controlled release MNS. synergistic action delivers antioxidant anti-inflammatory effects while influencing gut microbiota composition releasing short-chain fatty acids. Moreover, investigations revealed exhibited superior compared when administered orally. effectively downregulated NF-κB, NLRP3, Caspase-1, IL-1β expression upregulating MUC5AC expression, indicating enhanced protective thereby promoting mucosal healing. In addition, was found regulate immune cell downregulate neutrophil infiltration. armor- strategy elucidates impact nanomedicines on mitigating UC an effective treatment.

Язык: Английский

An anti-miR-301a and zinc coordination driven nanozyme loaded in nanoparticle for oral therapy of inflammatory bowel disease based on colitis microenvironment regulation DOI
Jiafeng Zou, Chuanhe Xia, Min Yao

и другие.

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 161997 - 161997

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Beta-Sitosterol-Conjugated Sinapic Acid-Engineered Nanoliposome: Biomucoadhesive and Enzyme-Responsive Targeted Oral Therapy in Ulcerative Colitis DOI

Kanika,

Ajay Kumar, Anas Ahmad

и другие.

ACS Applied Materials & Interfaces, Год журнала: 2025, Номер unknown

Опубликована: Апрель 29, 2025

Developing oral drug delivery systems is promising for ulcerative colitis (UC). However, the key challenges, including formulation degradation under harsh gastric conditions, poor targeting efficiency, and limited colonic residence, lead to therapeutic efficacy that still needs be tackled. Effective treatment requires a safe, efficacious, enzyme- pH-responsive, biomucoadhesive system overcome these challenges. Therefore, we have developed chitosan-armored 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) nanoliposomes amalgamated with synthesized beta-sitosterol-sinapic acid (Be-S) conjugate, further encapsulated 3,4-methylenedioxy-β-nitrostyrene (MNS) as NLRP3 inhibitor, termed C@MN@DMBe-S, limitation of free MNS sinapic acid. Formulated by thin-film hydration method processed through extrusion, unilamellar liposomes demonstrated structural stability mucoadhesive properties due chitosan coating. This configuration protected from acidic environment allowed retention in inflamed colon 48 h. The enzyme-responsive C@MN@DMBe-S nanoliposome releases at site via esterase activity, providing sustained controlled release MNS. synergistic action delivers antioxidant anti-inflammatory effects while influencing gut microbiota composition releasing short-chain fatty acids. Moreover, investigations revealed exhibited superior compared when administered orally. effectively downregulated NF-κB, NLRP3, Caspase-1, IL-1β expression upregulating MUC5AC expression, indicating enhanced protective thereby promoting mucosal healing. In addition, was found regulate immune cell downregulate neutrophil infiltration. armor- strategy elucidates impact nanomedicines on mitigating UC an effective treatment.

Язык: Английский

Процитировано

0